Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Elecoglipron

A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants

AstraZeneca · Phase 1 · Active, not recruiting · Enrollment 48

NCT07534592

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Group 1: Period 1n/rn/rn/rn/r
Group 1: Period 2n/rn/rn/rn/r
Group 1: Period 3n/rn/rn/rn/r
Group 1: Period 4n/rn/rn/rn/r
Group 1: Period 5n/rn/rn/rn/r
Group 1: Period 6n/rn/rn/rn/r
Group 2: Period 1n/rn/rn/rn/r
Group 2: Period 2n/rn/rn/rn/r
Group 2: Period 3n/rn/rn/rn/r
Group 2: Period 4n/rn/rn/rn/r
Group 2: Period 5n/rn/rn/rn/r
Group 2: Period 6n/rn/rn/rn/r
Group 2: Period 7n/rn/rn/rn/r

Not shown

  • Group 1: Period 1: endpoint not reported
  • Group 1: Period 2: endpoint not reported
  • Group 1: Period 3: endpoint not reported
  • Group 1: Period 4: endpoint not reported
  • Group 1: Period 5: endpoint not reported
  • Group 1: Period 6: endpoint not reported
  • Group 2: Period 1: endpoint not reported
  • Group 2: Period 2: endpoint not reported
  • Group 2: Period 3: endpoint not reported
  • Group 2: Period 4: endpoint not reported
  • Group 2: Period 5: endpoint not reported
  • Group 2: Period 6: endpoint not reported
  • Group 2: Period 7: endpoint not reported